LXEO

Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, announced today its abstract has been accepted to be presented at the International Congress of Parkinson's Disease and Movement Disorders 2026 taking place October 4-8, 2026 in Seoul, Korea. “We are pleased to see LX2006 featured at MDS 2026 through an oral presentation by Dr. Zesiewicz,” said Narinder Bhalla, MD, Chief Medical Officer of Lexeo Therapeutics.

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the second quarter 2026. “We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R.

RMAT designation granted based on recent interim clinical data from ongoing Phase I/II clinical trial evaluating LX2020 for PKP2-ACM

Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript

Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies